Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Merck
Express Scripts
Mallinckrodt
McKinsey
Healthtrust
Boehringer Ingelheim
Citi
US Army

Generated: May 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,469,182

« Back to Dashboard

Which drugs does patent 6,469,182 protect, and when does it expire?

Patent 6,469,182 protects HALAVEN and is included in one NDA.

This patent has thirty-eight patent family members in twenty-one countries.
Summary for Patent: 6,469,182
Title: Intermediates in the preparation of macrocyclic analogs
Abstract:Novel intermediates of the formula ##STR1## They are used in the preparation of macrocyclic analogs.
Inventor(s): Littlefield; Bruce A. (Andover, MA), Palme; Monica H. (San Jose, CA), Seletsky; Boris M. (Andover, MA), Towle; Murray J. (Auburn, NH), Yu; Melvin J. (Andover, MA), Zheng; Wanjun (Londonderry, NH)
Assignee: Eisai Co., Ltd. (Tokyo, JP)
Application Number:09/843,617
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 6,469,182

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Eisai Inc HALAVEN eribulin mesylate SOLUTION;INTRAVENOUS 201532-001 Nov 15, 2010 RX Yes Yes ➤ Sign Up ➤ Sign Up TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC LIPOSARCOMA ➤ Sign Up
Eisai Inc HALAVEN eribulin mesylate SOLUTION;INTRAVENOUS 201532-001 Nov 15, 2010 RX Yes Yes ➤ Sign Up ➤ Sign Up TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,469,182

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,653,341 Methods and compositions for use in treating cancer ➤ Sign Up
6,214,865 Macrocyclic analogs and methods of their use and preparation ➤ Sign Up
8,148,554 Methods and compositions for use in treating cancer ➤ Sign Up
8,097,648 Methods and compositions for use in treating cancer ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Colorcon
Cipla
Healthtrust
Fuji
US Department of Justice
Mallinckrodt
Fish and Richardson
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.